{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:31:13Z","timestamp":1791945073375,"version":"4.3.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two vaccines have been licensed to prevent chikungunya, a live attenuated vaccine (IXCHIQ) manufactured by Valneva and a virus-like particle chikungunya vaccine (VIMKUNYA) manufactured by Bavarian Nordic. One or both vaccines are now available in many countries globally, including Brazil, Canada, United Kingdom, United States and some European countries and territories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>While the absence of a head-to-head study limits comparative inferences, the two vaccines have several different characteristics that should be considered when advising individual travellers. We outline key information on the vaccines including immunogenicity and safety data, recommendations for use in travellers and guidance for use in pregnancy and breastfeeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Knowledge of the profiles and key features of the live attenuated and virus-like particle vaccines will enable healthcare providers to better advise travellers who are considering chikungunya vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jtm\/taaf118","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:57:39Z","timestamp":1763470659000},"source":"Crossref","is-referenced-by-count":12,"title":["Chikungunya vaccination for travellers: practical guidance for clinical decision-making"],"prefix":"10.1093","volume":"32","author":[{"given":"Susan L","family":"Hills","sequence":"first","affiliation":[{"name":"Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention , 3156 Rampart Rd, Fort Collins, CO, 80521 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Shlim","sequence":"additional","affiliation":[{"name":"Jackson Hole Travel & Tropical Medicine , PO Box 40, Kelly, WY, 83011 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Schofield","sequence":"additional","affiliation":[{"name":"2661 Dunrobin Rd , Ottawa, ON, K0A1T0 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E","family":"Wilson","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California , 550 16th St, San Francisco, CA, 94158 ,","place":["USA"]},{"name":"Department of Global Health and Population, Harvard T.H. Chan School of Public Health , 677 Huntington Ave, Boston, MA, 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D","family":"Barnett","sequence":"additional","affiliation":[{"name":"Section of Pediatric Infectious Diseases, Boston Medical Center , 850 Harrison Ave, Boston, MA, 02118 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin H","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mount Auburn Hospital , 330 Mount Auburn St, Cambridge, MA, 02138 ,","place":["USA"]},{"name":"Faculty of Medicine, Harvard Medical School , 25 Shattuck St, Boston, MA, 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J","family":"Christensen","sequence":"additional","affiliation":[{"name":"Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention , 3156 Rampart Rd, Fort Collins, CO, 80521 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Erin","family":"Staples","sequence":"additional","affiliation":[{"name":"Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention , 3156 Rampart Rd, Fort Collins, CO, 80521 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025121704475297200_ref1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517537","article-title":"Outbreak of chikungunya on Reunion Island: Early clinical and laboratory features in 157 adult patients","volume":"44","author":"Borgherini","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025121704475297200_ref2","author":"Lindsey","year":"2023"},{"key":"2025121704475297200_ref3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1017\/S0950268808001167","article-title":"Atypical chikungunya virus infections: Clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on R\u00e9union","volume":"137","author":"Economopoulou","year":"2009","journal-title":"Epidemiol Infect"},{"key":"2025121704475297200_ref4","author":"Food & Drug Administration"},{"key":"2025121704475297200_ref5","author":"Food & Drug Administration"},{"key":"2025121704475297200_ref6","doi-asserted-by":"crossref","first-page":"taaf039","DOI":"10.1093\/jtm\/taaf039","article-title":"A new non-live chikungunya vaccine for travellers","volume":"32","author":"Freedman","year":"2025","journal-title":"J Travel Med"},{"key":"2025121704475297200_ref7","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"2025121704475297200_ref8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: A phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"Lancet"},{"key":"2025121704475297200_ref9","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1016\/j.vaccine.2017.07.065","article-title":"Regulatory considerations in development of vaccines to prevent disease caused by chikungunya virus","volume":"35","author":"Yang","year":"2017","journal-title":"Vaccine"},{"key":"2025121704475297200_ref10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(24)00357-8","article-title":"Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: A single-arm, multicentre, phase 3b study","volume":"24","author":"McMahon","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025121704475297200_ref11","volume-title":"Presented at 19th Conference of the International Society of Travel Medicine, 2025 May 11\u201315","author":"Sattler","year":","},{"key":"2025121704475297200_ref12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1473-3099(24)00458-4","article-title":"Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: Interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents","volume":"25","author":"Buerger","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025121704475297200_ref13","author":"European Medicines Agency. Summary of product characteristics"},{"key":"2025121704475297200_ref14","doi-asserted-by":"crossref","first-page":"2500543","DOI":"10.2807\/1560-7917.ES.2025.30.32.2500543","article-title":"Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025","volume":"30","author":"Hills","year":"2025","journal-title":"Euro Surveill"},{"key":"2025121704475297200_ref15","volume-title":"Surveillance \u00e9pid\u00e9miologique \u00e0 La R\u00e9union","author":"Sante Publique France"},{"key":"2025121704475297200_ref16","author":"Sante Publique France. Surveillance \u00e9pid\u00e9miologique du chikungunya","year":"2025"},{"key":"2025121704475297200_ref17","article-title":"\u00c9pid\u00e9mie de chikungunya : Utilisation du vaccin IXCHIQ \u00e0 La R\u00e9union et \u00e0 Mayotte","author":"Haute autorite de sante"},{"key":"2025121704475297200_ref18","article-title":"Annex lV. Scientific conclusions","author":"European Medicines Agency"},{"key":"2025121704475297200_ref19","volume-title":"FDA Removes Recommended Pause in Use and Approves Required Updated Labeling","author":"Food & Drug Administration"},{"key":"2025121704475297200_ref20","doi-asserted-by":"crossref","first-page":"ofaf550","DOI":"10.1093\/ofid\/ofaf550","article-title":"Fatal adverse event after VLA1553 chikungunya vaccination in an elderly patient: A case report from Reunion Island","volume":"12","author":"Mosnier","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025121704475297200_ref21","volume-title":"Suspension Memo of Biologics License 1909 - IXCHIQ","author":"Food & Drug Administration"},{"key":"2025121704475297200_ref22","article-title":"Clinical guidance for use of live attenuated chikungunya vaccine among pregnant and breastfeeding individuals","author":"Hills","journal-title":"Advisory Committee on Immunization Practices Meeting; 2024 Feb 28"},{"key":"2025121704475297200_ref23","volume-title":"BLA Clinical Review Memorandum. IXCHIQ","author":"Food & Drug Administration"},{"key":"2025121704475297200_ref24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/INF.0000000000001658","article-title":"First detection of chikungunya virus in breast milk","volume":"36","author":"Campos","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2025121704475297200_ref25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.trsl.2022.12.001","article-title":"Breastfeeding by chikungunya virus-infected dams confers resistance to challenge in the offspring","volume":"255","author":"Paula","year":"2023","journal-title":"Transl Res"},{"key":"2025121704475297200_ref26","volume-title":"Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ\u00ae","author":"Valneva","year":"5, 2025"},{"key":"2025121704475297200_ref27","volume-title":"Valneva Receives First Marketing Authorization for IXCHIQ\u00ae in a Chikungunya Endemic Country","author":"Valneva"},{"key":"2025121704475297200_ref28","volume-title":"Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India","author":"Valneva"},{"key":"2025121704475297200_ref29","volume-title":"EMA Starts Review of Ixchiq (Live Attenuated Chikungunya Vaccine)","author":"European Medicines Agency","year":"2025"},{"key":"2025121704475297200_ref30","volume-title":"FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older while Postmarketing Safety Reports Are Investigated","author":"Food & Drug Administration","year":"2025"},{"key":"2025121704475297200_ref31","volume-title":"Ixchiq: Temporary Restriction on Vaccinating People 65 Years and Older to be Lifted","author":"European Medicines Agency"},{"key":"2025121704475297200_ref32","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(25)00552-3","article-title":"More data needed on the FDA's decision to suspend Ixchiq","volume":"25","author":"Lancet Infectious Diseases","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025121704475297200_ref33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: A phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"Lancet"},{"key":"2025121704475297200_ref34","article-title":"Clinical guidance for use of virus-like particle chikungunya vaccine in pregnant and breastfeeding women","author":"Hills","journal-title":"Advisory Committee on Immunization Practices meeting, 16 April, 2025"},{"key":"2025121704475297200_ref35","volume-title":"Approval Letter \u2013 VIMKUNYA","author":"Food & Drug Administration"},{"key":"2025121704475297200_ref36","volume-title":"Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children","author":"Bavarian Nordic"},{"key":"2025121704475297200_ref37","volume-title":"Bavarian Nordic Partners with Biologic E Limited to Expand Global Access to Chikungunya Vaccine","author":"Bavarian Nordic"},{"key":"2025121704475297200_ref38","article-title":"Evidence to Recommendations and proposed recommendations for use of virus-like particle chikungunya vaccine among adolescent and adults travelers","volume-title":"Advisory Committee on Immunization Practices meeting, 16 April, 2025","author":"Hills"},{"key":"2025121704475297200_ref39","volume-title":"ACIP Recommendations","author":"Centers for Disease Control and Prevention"},{"key":"2025121704475297200_ref40","volume-title":"Areas at Risk for Chikungunya","author":"Centers for Disease Control and Prevention"},{"key":"2025121704475297200_ref41","volume-title":"Chikungunya Vaccine for U.S. Travelers\u2019 Decision Tree","author":"Centers for Disease Control and Prevention"},{"key":"2025121704475297200_ref42","volume-title":"Vaccination against Chikungunya","author":"Superior Health Council"},{"key":"2025121704475297200_ref43","volume-title":"Chikungunya","author":"Duodecim Terveyskirjasto"},{"key":"2025121704475297200_ref44","volume-title":"STIKO: Empfehlung Zur Impfung Gegen Chikungunya","author":"Robert Koch Institute"},{"key":"2025121704475297200_ref45","volume-title":"Vaccination against Chikungunya - Recommendation of the Swiss Expert Committee for Travel Medicine","author":"Swiss Society for Tropical and Travel Medicine"},{"key":"2025121704475297200_ref46","volume-title":"Chikungunya Vaccine in UK Travellers: JCVI Advice","author":"UK Department of Health & Social Care"},{"key":"2025121704475297200_ref47","volume-title":"Special Situations","author":"Centers for Disease Control and Prevention"},{"key":"2025121704475297200_ref48","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007-13","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taaf118\/65408014\/taaf118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/8\/taaf118\/65408014\/taaf118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/8\/taaf118\/65408014\/taaf118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:48:24Z","timestamp":1765964904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taaf118\/8329240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,11,20]]},"published-print":{"date-parts":[[2025,12,17]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taaf118","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,20]]},"article-number":"taaf118"}}